File photo by Tony Avelar/The Christian Science Monitor Mahmoud ElSohly oversees acres of marijuana plants in the deep south, a swath of the country the tide of medical marijuana legalization has yet to touch. But he’s not running an illegal operation — he’s a professor of pharmaceutics and head of the marijuana program at the […]

by

LONDON, Sept. 07, 2016 — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at […]

by

SAN DIEGO, CA–(Marketwired – September 07, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA), and its subsidiary HempMeds® today announced that the Company will be sponsoring a forum put on by the Association of Cannabis Professionals on Tuesday, September 7, featuring the two remaining candidates for City Attorney of San Diego City Mara Elliot… read […]

by

OTTAWA, ONTARIO–(Marketwired – Sept. 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the […]

by

A greenhouse filled with medical marijuana growing in Denver.(Photo: Trevor Hughes/USA TODAY) Corrections Clarifications: An earlier version of this story gave the incorrect states in which Pazoo Labs operates marijuana testing labs. They are Colorado and Nevada. DENVER — Marijuana users, researchers and investors are eager to hear whether federal officials will remove pot from […]

by

A group of rats high on THC, the main psychoactive ingredient in marijuana, chose to perform the easiest possible task to get a reward, according to research done at the University of British Columbia. In a test case of 29 rats, the majority preferred a harder challenge in order to gain a larger batch of sugary […]

by

Mahmoud ElSohly oversees acres of marijuana plants in the deep south, a swath of the country the tide of medical marijuana legalization has yet to touch. But he’s not running an illegal operation — he’s a professor of pharmaceutics and head of the marijuana program at the University of Mississippi, which holds an exclusive contract with the […]

by

DEVON, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial, STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis (OA)), of ZYN002 cannabidiol […]

by

OTTAWA, ONTARIO–(Marketwired – Sep 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the […]

by

OTTAWA, ONTARIO — (Marketwired) — 09/06/16 — PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP”), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company”) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the […]

by

Cannabinoids accomplish what Western medicine can’t – again! While approximately 138,000 American kids suffer from Tourette syndrome (TS) – roughly 1 in every 162 adolescents under the age of 17 – a single case study on treatment resistant Tourette syndrome indicates that cannabinoids may provide a therapeutic option; offering a hopeful light at the end […]

by

ONTARIO, CANADA — Patients with epilepsy frequently experiment with cannabis and most report experiencing subjective benefits following their use of the substance, according to data published online ahead of print in the journal Epilepsy Behavior. Canadian researchers surveyed the experiences of over 300 adult patients admitted to an epilepsy monitoring unit over a 14-month period. More […]

by

IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) — Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2016. John McDermott, Endologix Chairman and Chief Executive Officer, said, “We continue to deliver solid revenue growth above expectations and are very […]

by

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) said it was on track for an NDA (New Drug Application) filing for both its cannabis-derived Dravet Syndrome and Lennox-Gastaut Syndrome indications following positive Phase III trials. “We believe that these Phase III data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures […]

by